Albert Bourla, Dvm, Ph.d.
Group President of Pfizer Innovative Health
Albert Bourla is the group president of Pfizer Innovative Health at Pfizer Inc., one of the world’s premier innovative biopharmaceutical companies. Pfizer Innovative Health includes six business groups: Consumer Healthcare, Inflammation & Immunology, Internal Medicine (neuroscience and pain, and cardiovascular and metabolic), Oncology, Rare Disease and Vaccines. Each business group is committed to improving health with our innovative products from prevention to treatment to wellness – at every stage of life in communities across the globe. It also includes the Patient and Health Impact group, which is focused on developing solutions for increased patient access, demonstrating the value of our innovations, and ensuring broader business model innovation. Albert has almost 25 years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines. Before assuming his current role, Albert was the group president of Pfizer’s Global Vaccines, Oncology and Consumer Healthcare Business. Previously, he was president and general manager of Pfizer’s Established Products Business, where he led the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio (including legacy brands and generics).
Molecular Biology and Molecular genetics